A strategy update with IDL Diagnostics was held on November 27th at Redeye, where CEO Anders Hultman and the management team presented recent achievements, spotlighted key initiatives, and discussed future opportunities looking toward 2026 and beyond. After their presentation, Redeye analyst Oscar Bergman moderated a Q&A session.
IDL Diagnostics at EAU26
IDL Diagnostics attended the European Association of Urology (EAU) 2026 conference in London last week. We had valuable discussions with physicians who use our diagnostic biomarkers in clinical practice and research. A big thank you to everyone we met at EAU26! We...
